Up to 30 to 40 percent of patients with AAA disease
are considered unsuitable candidates for conventional endovascular aneurysm repair (EVAR).1 According to estimates from physicians across Europe and the United States, more than one-third of these patients have AAA proximal neck anatomies
In this view, we will discuss phenotypes of inflammatory cells, innate immune system, immunoglobulins, and key cytokines in the AAA disease
and provide novel mechanistic insight for the development of immune-targeted therapies.
Consequently, EVAR has become the gold standard for treatment of AAA disease.
Aortica was founded to design, manufacture, and market tools for treatment of patients with AAA disease who have aortic anatomy that limits their treatment options.
In New Zealand, 230 people died of AAA disease
The company's lead product, Aorfix, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomies, which are often present in advanced AAA disease
: mechanism, stratification, and treatment.
Thus, there is a growing amount of evidence in a variety of animal models that supports the key role inflammation plays in AAA disease.
This study then went further and showed that an angiogenesis inhibitor decreased the inflammatory response and attenuated AAA formation , results that suggest that angiogenesis inhibition should be further explored as it may expand therapeutic alternatives for the treatment of AAA disease.
This volume contains 28 full-length contributions by international specialists plus 20 more short papers, all discussing the pathobiology of AAA disease
. It is organized into five main sections, dealing with epidemiology and rupture prevention; animal models; enzymology and pharmacology; biological aspects of endovascular devices to repair AAA; and genetics and immunology.